Universal Vision Biotechnology (3218.TWO) Earnings Analysis
Universal Vision Biotechnology (3218.TWO) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it missed with EPS 3.38 TWD vs 3.59 TWD est (-5.8%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E 12.04.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 3218.TWO next report earnings?
No confirmed upcoming earnings date is currently scheduled for 3218.TWO. This page updates as the calendar is published.
3218.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | 3.38 TWD | 3.59 TWD | -5.8% | Miss |
| 2026-03-05 | 3.48 TWD | 3.47 TWD | +0.3% | Beat |
| 2025-11-12 | 4.04 TWD | 3.42 TWD | +18.1% | Beat |
| 2025-08-15 | 0.5 TWD | 3.53 TWD | -85.8% | Miss |
| 2025-03-06 | 2.8 TWD | 3.09 TWD | -9.4% | Miss |
| 2024-08-12 | 3.28 TWD | 3.16 TWD | +3.8% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
3218.TWO valuation and analyst view
| Trailing P/E | 12.04 |
|---|---|
| Trailing EPS | 11.019 TWD |
| Price / book | 3.25 |
| Dividend yield | 5.68% |
| Market cap | 11.73B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Universal Vision Biotechnology (3218.TWO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 3218.TWO. This page updates as the calendar is published.
Did 3218.TWO beat earnings last quarter?
In its 2026-05-11 report, 3218.TWO posted EPS of 3.38 TWD versus a 3.59 TWD estimate — a miss of 5.8%.
What is 3218.TWO's earnings track record?
Over the last 6 reported quarters with consensus data, 3218.TWO beat estimates 3 times (50%).
What is 3218.TWO's current P/E ratio and EPS?
3218.TWO trades at a trailing P/E of 12.04 on trailing EPS of 11.018784200119557 TWD.
What do analysts rate 3218.TWO?
3218.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.